Prevalence of Primary Aldosteronism in Patients With Resi... | NCT01459042

Studies
Prevalence of Primary Aldosteronism in Patients With Resistant Hypertension in China

NCT01459042

Sponsor

Shanghai Jiao Tong University School of Medicine

Status

Completed

Last Update Posted

Oct 25, 2011Estimated

Enrollment

2,000Estimated

Phase

Not provided

Conditions

Hypertension, Resistant to Conventional Therapy

Interventions

Not provided

Countries

China

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

Status Module

Record Verification Date

Oct 2011

Overall Recruitment Status or Expanded Access Status

Completed

Last Known Status

Not provided

Delayed Posting

Not provided

Why Stopped

Not provided

Expanded Access Info

Start Date

Jan 2010

Primary Completion Date

Oct 2011Actual

Completion Date

Not provided

First Submitted Date

Oct 21, 2011

First Submission Date that Met QC Criteria

Oct 24, 2011

First Posted Date

Oct 25, 2011Estimated

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

Oct 24, 2011

Last Update Posted Date

Oct 25, 2011Estimated

Sponsor/Collaborators Module

Responsible Party, by Official Title

Wang Weiqing, Endocrinology Department of Ruijin Hospital affiliated Shanghai Jiao Tong University School of Medicine, Shanghai Jiao Tong University School of MedicinePrincipal Investigator

Lead Sponsor

Shanghai Jiao Tong University School of MedicineOTHER

Collaborators

Not provided

Oversight Module

Has Data Monitoring Committee (DMC)

Yes

Is FDA Regulated Drug

Not provided

Is FDA Regulated Device

Not provided

Is Unapproved Device

Not provided

Pediatric Postmarket Surveillance of a Device Product

Not provided

Product Exported from US

Not provided

FDAAA801 Violation

Not provided

Description Module

Brief Summary

Recent studies indicate that primary aldosteronism (PA) is a much more common cause of hypertension than had been demonstrated historically. In patients with resistant hypertension, the prevalence of PA from different clinics worldwide is about 10-20%. As has been no such data in China, the investigators are conducting a PA study in different province of China to evaluate the prevalence of PA in patients with resistant hypertension.

Detailed Description

Not provided

Design Module

Study Type

Observational

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Not provided

Target Follow-Up Duration

Not provided

Phases

Not provided

Interventional Study Design

Allocation

Not provided

Intervention Model

Biospecimen

Retention

Enrollment

2,000Estimated

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

patients with resistant hypertension
age 18-65 years

Exclusion Criteria:

known cause of hypertension
heart failure
renal dysfunction
Stroke, transient ischaemic attack or myocardial infarction in the past 6 months
cirrhosis
pregnancy
undertreatment of glucocorticoid

Accepts Healthy Volunteers

Sex

All

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

18 Years

Maximum Age

65 Years

Standard Ages

AdultOlder Adult

Study Population

Patients with resistant hypertension from different provinces of China

Sampling Method

Probability Sample

Contacts/Locations Module

Central Contacts

Not provided

Overall Officials

Name	Affiliation	Role
Weiqing Wang, MD, PhD	Endocrinology Department of Ruijin Hospital affiliated Shanghai Jiao Tong University School of Medicine	Principal Investigator

Locations

Facility	Status	City	State	ZIP	Country	Contacts
Dep.endocrinology of Shanghai Ruijin Hospital, Shanghai Jiaotong university school of medcine		Shanghai	Shanghai Municipality	200025	China

Condition Browse Module

MeSH Terms

ID	Term
C563514	Hypertension Resistant to Conventional Therapy

Ancestor Terms

Not provided

Browse Leaves

Not provided

Browse Branches

Not provided